Enabling Novel Vaccine Discovery
Designed to increase the efficiency and quality of vaccine discovery, Genedata's purpose-built, end-to-end enterprise platform supports the full discovery process and enables faster testing, simplified production, and reduced costs.
Vaccines
In addition to classical vaccine R&D approaches, Genedata Biologics supports novel vaccine technologies such as synthetic self-amplifying mRNA, which accelerates vaccine development by utilizing synthetic and cell-free processes. The platform paves the way for the discovery of novel vaccines, even for antigens that are extremely difficult to produce and formulate.
